Equity Overview
Price & Market Data
Price: $1.23
Daily Change: $0.00 / 0.00%
Daily Range: $1.15 - $1.30
Market Cap: $49,600,388
Daily Volume: 38,132
Performance Metrics
1 Week: -4.07%
1 Month: 29.26%
3 Months: -35.16%
6 Months: 30.72%
1 Year: -20.81%
YTD: -24.36%
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.